Item 7.01 Regulation FD Disclosure.
On March 20, 2023, MyMD Pharmaceuticals, Inc. (the “Company”) issued a press
release announcing that it will present data from a preclinical study of its
MYMD-1® product candidate in a rheumatoid arthritis (RA) model at the 2023
Society of Toxicology Annual Meeting. The Company undertakes no obligation to
update, supplement or amend the materials attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this
Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not
be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Exchange Act or the Securities Act of 1933, as amended,
except as shall be expressly set forth by reference in such a filing.
Furthermore, the furnishing of information under Item 7.01 of this Current
Report on Form 8-K is not intended to constitute a determination by the Company
that the information contained herein, including the exhibits hereto, is
material or that the dissemination of such information is required by Regulation
FD.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number Description
99.1 Press Release, dated March 20, 2023 (furnished herewith
pursuant to Item 7.01)
104 Cover Page Interactive Data File (formatted as Inline XBRL)
© Edgar Online, source Glimpses
postbrexitcompliance.com 